NASDAQ:KRYS - Krystal Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Krystal Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $64.35 -0.16 (-0.25 %) (As of 02/16/2020 02:58 PM ET) Add Today's Range$62.58Now: $64.35▼$65.4850-Day Range$47.06MA: $55.88▼$65.6452-Week Range$18.50Now: $64.35▼$66.85Volume144,307 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:KRYS Previous Symbol CUSIPN/A CIK1711279 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees37 Outstanding SharesN/AMarket CapN/A Next Earnings Date3/10/2020 (Estimated) OptionableNot Optionable Receive KRYS News and Ratings via Email Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KRYS Rates by TradingView Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." How were Krystal Biotech's earnings last quarter? Krystal Biotech Inc (NASDAQ:KRYS) announced its quarterly earnings results on Monday, November, 4th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.14. View Krystal Biotech's Earnings History. When is Krystal Biotech's next earnings date? Krystal Biotech is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Krystal Biotech. What price target have analysts set for KRYS? 6 equities research analysts have issued 1-year target prices for Krystal Biotech's stock. Their forecasts range from $59.00 to $90.00. On average, they anticipate Krystal Biotech's share price to reach $72.50 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for Krystal Biotech. What is the consensus analysts' recommendation for Krystal Biotech? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech. What are Wall Street analysts saying about Krystal Biotech stock? Here are some recent quotes from research analysts about Krystal Biotech stock: 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (1/4/2020) 2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019) 3. Chardan Capital analysts commented, "We view the receipt of the FDA Therapy (RMAT) designation as a significant positive for the timelines on KB103. This news follows KB103 receiving the EMA Priority Medicines (PRIME) designation on 29 March. As we have noted, Krystal’s market cap is modest relative to companies with PRIME and/or RMAT/BTD designations. We again reiterate: We would not be surprised if Krystal’s market cap crosses $1 billion by 2020E. On today’s news, we update our detailed model, moving the probability of KB103 launch from 55% to 67%, leading to an increase in our 2030E KB103 sales estimate from $492.1 mm to $596.5 mm. With a reduction in our WACC from 12.4% to 11.9%, these changes lead to a 30% KRYS PT target increase, from $57.50 to $75. has demonstrated impressive wound closure data (albeit in small numbers of patients) in the GEM-1 and GEM-2 studies." (6/24/2019) 4. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our target to $38 from $32. The changes to our valuation include: (1) adjustment to base year to reflect the current NPV relative to our September 2018 initiation of coverage; and (2) increasing our projected chance of success for to 15%. We are currently leaving our projected chance of success for KB103 the same, at 25%, and await the pending clinical update this quarter." (5/24/2019) 5. William Blair analysts commented, "We continue to view the anticipated second quarter clinical update of the GEM trial as a significant near-term catalyst for shares. As we have noted previously (see our note, We See Durable Wound Closure and 30%-40% COL7A1 Expression as after reviewing the published literature, we believe that achieving roughly 30%-40% of wild-type (normal) levels of collagen VII could be sufficient to restore skin integrity and prevent skin blistering. We also believe that the presence of anchoring fibrils should be viewed qualitatively only due to its lack of direct correlation with clinical results." (5/6/2019) Has Krystal Biotech been receiving favorable news coverage? Media stories about KRYS stock have trended neutral this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Krystal Biotech. Are investors shorting Krystal Biotech? Krystal Biotech saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,590,000 shares, an increase of 8.2% from the January 15th total of 1,470,000 shares. Based on an average daily volume of 171,700 shares, the short-interest ratio is presently 9.3 days. Approximately 14.7% of the shares of the company are sold short. View Krystal Biotech's Current Options Chain. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Momo (MOMO) and Portola Pharmaceuticals (PTLA). Who are Krystal Biotech's key executives? Krystal Biotech's management team includes the folowing people: Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)Ms. Pooja Agarwal, VP of Product Devel. (Age 40)Mr. Antony A. Riley, Chief Financial Officer (Age 51)Ms. Gloria Lin, Accounting Mang. When did Krystal Biotech IPO? (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (2.64%), Credit Suisse AG (1.62%), Pictet Asset Management Ltd. (1.22%), Lord Abbett & CO. LLC (0.94%), Goldman Sachs Group Inc. (0.46%) and Nicholas Investment Partners LP (0.43%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech. Which major investors are selling Krystal Biotech stock? KRYS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Nicholas Investment Partners LP, EAM Investors LLC, Chartwell Investment Partners LLC, UBS Group AG, Garnet Equity Capital Holdings Inc., Rafferty Asset Management LLC and Pictet Asset Management Ltd.. Company insiders that have sold Krystal Biotech company stock in the last year include Daniel Janney, Krish S Krishnan and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech. Which major investors are buying Krystal Biotech stock? KRYS stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Goldman Sachs Group Inc., Citigroup Inc., California Public Employees Retirement System, Virtu Financial LLC, Blair William & Co. IL, UBS Asset Management Americas Inc. and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have bought Krystal Biotech stock in the last two years include Antony A Riley, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech. How do I buy shares of Krystal Biotech? Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $64.35. MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 218 (Vote Outperform)Underperform Votes: 223 (Vote Underperform)Total Votes: 441MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: Trading based on a resistance level
